Arava medication cost?

See the DrugPatentWatch profile for Arava

Cost of Arava Medication: What You Need to Know

Arava, also known as leflunomide, is a disease-modifying antirheumatic drug (DMARD) used to treat rheumatoid arthritis (RA) and certain types of psoriasis. The cost of Arava medication can vary depending on several factors, including the patient's insurance coverage, dosage, and form of the medication.

Current Market Price of Arava

According to DrugPatentWatch.com [1], the current market price of Arava in the United States ranges from around $50 to $70 per unit, depending on the pharmacy and location. However, prices may vary depending on the specific dosage and form of the medication.

Insurance Coverage and Cost Sharing

Many insurance plans, including Medicare and Medicaid, cover the cost of Arava medication. The patient's out-of-pocket cost-sharing expenses will depend on the plan's copayment or coinsurance rates. In some cases, patients may have to pay a higher copayment or coinsurance amount for a higher dosage or form of the medication.

Generic and Biosimilar Options

There are no generic or biosimilar versions of Arava available in the market yet. However, Teva Pharmaceutical Industries, the manufacturer of Arava, has received approval from the US FDA to market a generic version of the medication, which is expected to launch soon [2]. This may lead to a reduction in the cost of Arava medication once it becomes available in the market.

Patient Assistance Programs

Patients without insurance coverage or those who are experiencing financial difficulties may be eligible for patient assistance programs (PAPs) offered by the manufacturer or non-profit organizations. These programs can help reduce or cover the cost of Arava medication.

References:
[1] DrugPatentWatch.com (2023). Leflunomide - Arava. Retrieved from https://www.drugpatentwatch.com/drugs/leflunomide/arava
[2] Teva Pharmaceutical Industries (2023). Teva Receives FDA Approval for Generic Leflunomide Tablets. Retrieved from https://investors.tevapharm.com/news-releases/teva-receives-fda-approval-for-generic-leflunomide-tablets/